1.A Case of Type 2 Diabetes with Ipragliflozin Administration Developing Euglycemic Diabetic Ketoacidosis Due to Reduced Food Intake Following Colonoscopy
Takamasa OSAKI ; Shusaku TOMITA ; Takahiro HARADA ; Shoko MATSUMOTO ; Hiroyuki SAITO
An Official Journal of the Japan Primary Care Association 2024;47(1):12-16
The patient was an 80-year-old woman with type 2 diabetes mellitus taking ipragliflozin. She underwent a colonoscopy one week prior to admission. After the colonoscopy, she felt exhausted and lost her appetite. On the day of admission, she was admitted to the emergency department because of abdominal pain and repeated vomiting. Physical examination and chest and abdominal CT were performed; however, no cause was identified for the abdominal pain or vomiting. Blood gas analysis showed high anion gap metabolic acidosis. Serum ketones were elevated to 6,045/μL and plasma glucose concentration was 182 mg/dL. We diagnosed ipragliflozin-induced euglycemic diabetic ketoacidosis (euDKA) and discontinued the drug. Ketoacidosis improved with administration of intravenous fluids and insulin injections. Her abdominal pain and vomiting improved. It is important to recognise that patients taking SGLT2 inhibitors may develop euDKA, as in this case, due to fasting after colonoscopy or reduced food intake after the procedure, and to discontinue SGLT2 inhibitors at least 2 days before the procedure.
2.The Open Clinical Tests for the Safety of Kurozu-containing Food
Shoko ABE ; Yoshiyuki MATSUMOTO ; Satoshi KOYANAGI
Japanese Journal of Complementary and Alternative Medicine 2019;16(1):7-12
Two different types of clinical safety test of Kurozu-containing food were done. Under the informed consent, following tests were conducted, Test 1; Ten healthy adults were orally administrated 10 capslues/day of Kurozu for 4 weeks, Test 2; Ten patients with hepatitis C and 10 patients with mild hepatic dysfunction were orally administrated 2 capslues/day of Krozu for 4 weeks. In both the Test1 and Test2, Vital sign including Blood pressure etc, blood cell count, blood chemical analysis, and urinalysis were performed. In both tests, there were no abnormal findings. Furthermore, no side effect was observed. In conclusion, safety of Kurozu-containing food was confirmed.
3.The Excessive Consumption Test for the Safety of Black Sesame Extract
Yoshiyuki MATSUMOTO ; Shoko ABE ; Satoshi KOYANAGI
Japanese Journal of Complementary and Alternative Medicine 2020;17(1):7-10
The excessive consumption test for the safety of black sesame extract (BSE) was conducted. Eleven healthy adults (male 6,female 5) were orally administered 5 tablets/day of BSE for 4 weeks. There were no abnormal changes in blood and urinary analysis. In addition, no serious adverse effects were observed. These results indicate that the excessive dose of BSE is safe for healthy adults.
4.Effects of Dietary Supplement Containing Kurozu Concentrate on Visceral Fat Accumulation
Shoko ABE ; Masao HASEGAWA ; Junichi TSURUOKA ; Yoshiyuki MATSUMOTO ; Satoshi KOYANAGI
Japanese Journal of Complementary and Alternative Medicine 2019;16(1):13-19
Objective: The present study was done to examine the effect of dietary supplement containing Kurozu concentrate on human visceral fat accumulation. Material and Methods: Sixteen subjects(BMI≧25) were orally administrated Kurozu concentrate for 8 weeks(low dose group: 500 mg/day, high dose group 1000 mg/day). Before and at weeks 8, hematological analysis, urinalysis and CT-scan to estimate the visceral fat accumulation were conducted. Results: In high dose group, following results were obtained; visceral fat decreased significantly(p=0.033), HDL-cholesterol level elevated significantly (p=0.034) and systolic blood pressure decreased significantly(p=0.004). In addition, no serious symptoms or abnormal hematological values were observed in both group.Conclusions: The dietary supplement containing Kurozu concentrate may be useful to prevent a metabolic syndrome.
5.Palliative Radiation Therapy for Choroidal Metastases: A Report of Three Cases
Takashige KIYOTA ; Shoko TAKATA ; Akira MATSUMOTO ; Makoto OTSUKA ; Maho ITOTANI ; Toru ADACHI ; Ryoko OKI ; Kenichi KIMOTO ; Atsushi OSOEGAWA ; Kenji SUGIO ; Kazuo NISHIKAWA ; Haruto NISHIDA ; Tsutomu DAA ; Yoshiki ASAYAMA
Palliative Care Research 2022;17(1):17-22
We here report three cases of choroidal metastases with ocular pain and visual symptoms treated with palliative irradiation. Case 1: A 71-year-old woman was treated with chemotherapy for multiple metastases after surgery for right breast cancer. Sixteen years after surgery, a right choroidal metastasis with ocular pain and visual disturbance was detected. Palliative irradiation to this lesion achieved reduction in ocular pain and shrank the tumor. Case 2: A 54-year-old man presented with right ocular pain and abnormal vision and was diagnosed as having right lung cancer with multiple systemic metastases. Palliative irradiation to a right choroidal metastasis achieved reduction in ocular pain and shrank the tumor. Case 3: A 71-year-old woman developed left eye pain 17 months after surgery for lung cancer in the right upper lobe. She was diagnosed as having a left choroidal metastasis. After palliative irradiation, the tumor shrank and the left eye pain temporarily resolved. Palliative radiation therapy for choroidal metastasis with ocular pain and visual symptoms seems to be effective in improving symptoms.